utpatents-US5866323
Download pdf
Abstract/Description: | This invention is based on the discovery that the type II TGF-beta receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis. |
---|---|
Subject(s): | 435/6.11 435/6.1 435/7.1 435/7.2 435/7.21 435/7.23 436/503 436/811 |
Date Issued: | 1999-02-02 |
Title: | Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor beta and homologous growth controlling factors. |
|
---|---|---|
Name(s): |
Case Western Reserve University; Medical College of Ohio, assignee Markowitz, Sanford D., inventor Brattain, Michael G., inventor Willson V, James K., inventor |
|
Type of Resource: | text | |
Genre: | patent | |
Publisher: | United States Patent and Trademark Office | |
Other Date: | Date Filed: 1995-05-22 | |
Date Issued: | 1999-02-02 | |
Physical Form: | application/pdf | |
Extent: | 27 p. | |
Abstract/Description: | This invention is based on the discovery that the type II TGF-beta receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis. | |
Identifier(s): |
utpatents-US5866323 (IID) Patent No.: US5866323 (patno) Appl. No.: 08/445520 (appno) |
|
Subject(s): |
435/6.11 435/6.1 435/7.1 435/7.2 435/7.21 435/7.23 436/503 436/811 |
|
Held by: | United States Patent and Trademark Office (USPTO) Public Search Facility | |
Location: | University of Toledo Digital Repository | |
Rights Statement: | No Copyright - United States | |
In Collections: |